Sotagliflozin: A Potential Test Of Patient-Physician Decision-Making
Executive Summary
Sanofi's proposed type 1 diabetes treatment may be beneficial for some patients who want more glycemic control and are willing to perform the necessary monitoring, but how would the US FDA define that population in the label?
You may also be interested in...
Rx Spending Growth To Be Driven By New Drug Entries, CMS Says
Advances in cancer, diabetes, and Alzheimer's could lead to expensive new treatments, contributing to spending increases in next decade, according to CMS projections.
US FDA Shuttering More Operations As User Fee Money Dwindles
Compounding carryover money runs out, crippling some activities although inspections will continue; countdown to the end of PDUFA fee balance continues.
Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee
Some Endocrinologic and Metabolic Drugs Advisory Committee members said a REMS is sufficient, but others worried that proposed risk management plans were not proven effective.